Nature’s Sunshine Products, Inc. — FY2022 Form 10-K
Reporting period: Year ended December 31, 2022; comparisons are to FY2021. This annual filing does not provide a standalone Q4 financial summary. Nature’s Sunshine manufactures and sells nutritional and personal care products, primarily through independent consultants, across four geographic segments.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net sales | $421.9 million | $444.1 million |
| Gross profit / margin | $299.8 million / 71.0% | $328.6 million / 74.0% |
| Operating income / margin | $16.3 million / 3.8% | $34.7 million / 7.8% |
| Consolidated net income | $0.6 million | $30.2 million |
| Net income attributable to common shareholders; diluted EPS | $(0.4) million; $(0.02) | $28.9 million; $1.42 |
| Cash from operating activities | $0.7 million | $34.6 million |
- Net sales declined 5.0% in U.S. dollars, but increased 0.2% excluding foreign-exchange effects. Currency translation reduced sales by approximately $23.1 million.
- Operating cash flow fell substantially, reflecting lower gross margins and timing of working-capital payments and receipts. Capital expenditures were $7.6 million.
- Year-end cash and equivalents were $60.0 million, including $51.2 million held by foreign subsidiaries and potentially subject to repatriation taxes or restrictions. Working capital was $83.9 million, down from $88.0 million.
- Debt included $1.2 million outstanding under an equipment financing agreement, classified as current. The $25 million revolving facility had no year-end borrowings and matures July 2027; the company reported compliance with its covenants.
- Total assets were $229.8 million and total liabilities were $82.7 million. The company repurchased 909,000 shares for $13.6 million in 2022; no dividend was declared.
Material changes versus FY2021
- Sales fell in Europe (13.7%), North America (11.0%), and Latin America and Other (9.7%); Asia grew 5.3% in reported dollars and 16.1% in local currencies. Asia’s results included strong Taiwan growth, while China sales declined 18.3% amid COVID-related restrictions.
- Cost of sales rose to 29.0% of sales from 26.0%; gross margin contracted 3.0 percentage points. The company recorded $5.3 million of incremental inventory valuation charges, including $1.0 million related to the Russia-Ukraine conflict.
- SG&A declined $1.0 million to $153.1 million, but increased to 36.3% of sales from 34.7%, in part because revenue fell. Volume incentives declined to 30.9% of sales from 31.5%.
- The effective tax rate rose to 96.4% from 5.1%, largely due to a $9.4 million increase in the valuation allowance against deferred tax assets. The allowance was $18.0 million at year-end.
- Cash declined by $26.2 million to $60.0 million. 2022 financing included $13.6 million of repurchases; unlike 2021, there was no $19.9 million special dividend.
Outlook, risks, contingencies, and unusual items
- Outlook: No numerical revenue or earnings guidance is provided. Management says cash from operations and available cash are expected to fund normal operating needs and capital expenditures, while noting that downturns, weaker demand, tax outcomes, and contingencies could impair longer-term liquidity.
- Management cites inflation and higher input, labor, production, and transportation costs; supply-chain and ingredient availability; foreign-exchange exposure; COVID-related disruption in China; and the continuing Russia-Ukraine conflict as pressures on results. Russia and Other sales declined to $53.3 million from $61.4 million, and operating income before specified charges fell to $2.9 million from $5.8 million.
- Subsequent event: A fraud scheme targeting the company’s Japan subsidiary caused $4.8 million of unauthorized wire transfers in February 2023. The company expected a one-time pre-tax charge of up to $4.8 million in Q1 2023 and was pursuing recovery; the filing says it found no evidence of additional fraud or consumer-data access.
- Controls: Management and Deloitte concluded internal control over financial reporting was ineffective because of a material weakness in controls over Japan subsidiary wire transfers. Remediation was underway but incomplete at filing. Deloitte’s financial-statement audit opinion was unqualified.
- Reported contingencies include $0.3 million accrued for non-income-tax matters, with potential future payments estimated at $0–$2.9 million, and $0.6 million accrued for other litigation, with additional possible losses estimated at $0–$0.3 million. Management cautions outcomes remain uncertain.
- Other significant risks include regulation of dietary supplements, product and earnings claims, direct-selling practices and consultant classification; dependence on independent consultants and key sales networks; product liability; China product registrations and joint-venture operations; and cybersecurity and privacy risks.
Important facts for investors to verify
- Whether sales trends, consultant activity, and margins stabilize, particularly in North America, Europe, and China, and whether Asia’s growth persists.
- Whether inventory reserves, inflationary costs, and supply-chain constraints require further charges or continue to pressure gross margin and cash conversion.
- The cash-flow and tax consequences of foreign-held cash, deferred-tax-asset valuation allowances, expiring foreign tax credits, and any tax-authority assessments.
- Recovery, insurance coverage, final accounting, and completed remediation related to the $4.8 million Japan wire-fraud incident and material control weakness.
- Developments in Russia and Ukraine, China’s operating restrictions, direct-selling regulation, and disclosed tax and litigation contingencies.